Where does Dyne Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$120.85M-7.9%	-$111.96M-3.6%	-$108.04M+2.5%	-$110.86M+3.9%	-$115.36M-28.8%
Depreciation and amortization	$550K+5.6%	$521K+4.2%	$500K0.0%	$500K-0.4%	$502K+11.6%
Stock-based compensation	$13.08M+16.5%	$11.23M+1.3%	$11.08M+5.3%	$10.52M-19.2%	$13.02M+24.3%
Gain (loss) on sale of assets	-$30K—	——	——	——	-$95K-28.4%
Change in accounts payable	-$4.8M—	——	$18.47M—	——	-$8.6M-768%
Change in other assets	-$28K—	$0-100%	$15.79M+665%	-$2.8M—	$0—
Net cash from operating activities	-$144.92M-29.6%	-$111.83M-23.2%	-$90.78M+4.1%	-$94.7M+10.6%	-$105.89M-25.6%
Capital expenditures	$221K-54.3%	$484K+22.5%	$395K+558%	$60K-93.9%	$981K-8.7%
Net cash from investing activities	-$2.39M—	$0+100%	-$37.97M-660%	$6.77M+365%	$1.46M+109%
Proceeds from issuance of debt	——	$49.45M—	——	——	——
Proceeds from issuance of common stock	$0-100%	$377.7M+75.0%	$215.8M—	——	$140.65M—
Payment of debt issuance costs	$30K+233%	$9K—	——	——	$0—
Net cash from financing activities	$7.06M-98.4%	$430.97M+98.3%	$217.33M+116%	$100.77M-28.7%	$141.24M+3,785%
Net increase (decrease) in cash	-$140.25M-144%	$320.12M+261%	$88.58M+590%	$12.85M-65.1%	$36.81M—
Interest paid	$3.63M+44.5%	$2.52M—	——	——	$0—
Gain (Loss) on Disposition of Assets	-$30K—	——	——	——	-$95K-28.4%
Increase (Decrease) in Accounts Payable and Other Operating Liabilities	-$4.8M—	——	$18.47M—	——	-$8.6M-768%
Increase (Decrease) in Prepaid Expense and Other Assets	$32.85M—	——	-$389K—	——	-$5M-222%
Non Cash Lease Expense	$116K+231%	$35K-63.5%	$96K—	——	$75K-44.9%
Payments To Acquire Other Productive Assets	——	$4.7M0.0%	$4.7M0.0%	$4.7M0.0%	$4.7M—
Payment Of Issuance Costs From Public Offering Of Common Stock	$424K—	——	——	——	$0—
Payments Of Debt Issuance Costs	$30K+233%	$9K—	——	——	$0—
Proceeds From Vendor Financing Arrangement	$6.79M—	——	——	——	$0—
Repayments Under Vendor Financing Arrangement	$579K—	——	——	——	$0—
Accrued payables for capital expenditures	$77K+18.5%	$65K+118%	-$364K-209%	$335K+1,055%	$29K+160%
Offering Costs Included In Accounts Payable Or Accrued Expenses	——	$106K0.0%	$106K0.0%	$106K0.0%	$106K—
Free cash flow	-$145.14M-29.2%	-$112.32M-23.2%	-$91.17M+3.8%	-$94.76M+11.3%	-$106.87M-25.1%
Free cash flow	-$145.14M-29.2%	-$112.32M-23.2%	-$91.17M+3.8%	-$94.76M+11.3%	-$106.87M-25.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Dyne Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Dyne Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.